Your session is about to expire
← Back to Search
Drug-Eluting Stent
SELUTION SLR DCB vs. "-limus" DES for Coronary Artery Disease
N/A
Recruiting
Led By Ron Waksman, MD
Research Sponsored by M.A. Med Alliance S.A.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
Study Summary
This trial tests the safety and effectiveness of a new type of PTCA DEB for treating narrowed coronary vessels. It will involve 910 people from the US, Canada, Brazil, Japan and Europe.
Who is the study for?
This trial is for adults with small vessel coronary artery disease who need PCI and can tolerate dual antiplatelet therapy. They should not be pregnant, planning surgery within 30 days, or have severe heart failure. Participants must be willing to follow study procedures and use contraception if applicable.Check my eligibility
What is being tested?
The SELUTION SLR DCB device is being tested against FDA-approved '-limus' DES in treating de novo lesions in small coronary vessels. This randomized controlled trial aims to enroll up to 910 subjects across multiple countries.See study design
What are the potential side effects?
Potential side effects may include reactions related to the devices used for PCI, bleeding due to antiplatelet therapy, and typical risks associated with catheter-based cardiac procedures such as bruising or infection at the catheter insertion site.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Target lesion failure (TLF)
Secondary outcome measures
All-Cause Mortality
Bleeding Academic Research Consortium (BARC) class 2-5
Cardiovascular Mortality
+14 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: SELUTION SLR 014 PTCA DEBExperimental Treatment1 Intervention
SELUTION Sustained Limus Release (SLR) 014 Percutaneous Transluminal Coronary Angioplasty (PTCA) Drug Eluting Balloon (DEB)
The SELUTION SLR 014 PTCA DEB is a minimally invasive, single use and sterile Sirolimus coated PTCA balloon catheter.
The SELUTION SLR 014 PTCA DEB is available with balloon diameters from 2.0 to 3.0 mm and lengths of 15 to 40 mm for the purpose of the De Novo IDE trial
Group II: Control TreatmentActive Control1 Intervention
any FDA approved "limus-based" Drug Eluting Stent, as per standard institutional practice
Find a Location
Who is running the clinical trial?
M.A. Med Alliance S.A.Lead Sponsor
8 Previous Clinical Trials
5,331 Total Patients Enrolled
1 Trials studying Coronary Artery Disease
3,326 Patients Enrolled for Coronary Artery Disease
Ron Waksman, MDPrincipal InvestigatorMedstar Washington Hospital Center
24 Previous Clinical Trials
13,294 Total Patients Enrolled
9 Trials studying Coronary Artery Disease
11,636 Patients Enrolled for Coronary Artery Disease
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My target lesion is highly likely (>70%) to respond well to specific pre-treatment and DEB.I am scheduled for treatment on a lesion near the beginning of my aorta.I am allergic to Sirolimus or similar medications.I am scheduled for a procedure to open a blocked artery within 30 days after my initial treatment.I have had severe heart failure in the last 6 months.I haven't had a peptic ulcer or GI bleeding in the last 6 months.I am pregnant, breastfeeding, or might become pregnant within a year after the procedure.I tested positive for COVID-19 within 24 hours before my procedure.I am 18 years old or older.I can take aspirin and another blood thinner without issues.I am not pregnant or I am using birth control.My target lesion is in the left main artery or a graft.I have a heart condition that requires a procedure to open blocked arteries.My target lesions meet the trial's specific criteria.I have one treatable lesion in a single blood vessel, with no other lesions in that vessel.I have had successful treatment on up to 2 non-target lesions before this trial.My heart's blood flow is reduced but not completely blocked.My heart condition involves a main artery or its major branch.I have a lesion near a vessel split, but only one vessel needs treatment.I have unstable heart symptoms, including ongoing chest pain.I had a severe heart attack within the last 30 days.I am scheduled for a major surgery within 30 days after the initial procedure.
Research Study Groups:
This trial has the following groups:- Group 1: SELUTION SLR 014 PTCA DEB
- Group 2: Control Treatment
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is there currently an opportunity for participants to join this experiment?
"The trial described on clinicaltrials.gov is not presently open to recruitment, despite being initially posted in July of 2023 and last updated just days ago. Nevertheless, there are 548 other ongoing trials actively seeking volunteers at this moment."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger